# Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

> **NCT05518201** · PHASE1 · COMPLETED · sponsor: **Shanghai Bovax Biotechnology Co., Ltd.** · enrollment: 90 (actual)

## Conditions studied

- Penile Cancer
- Anal Cancer
- PIN-1
- PIN-2
- PIN-3
- AIN1
- AIN2
- AIN3
- Genital Wart

## Interventions

- **BIOLOGICAL:** Placebo among 18-45 yrs
- **BIOLOGICAL:** Placebo among 9-17 yrs

## Key facts

- **NCT ID:** NCT05518201
- **Lead sponsor:** Shanghai Bovax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-23
- **Primary completion:** 2023-11-20
- **Final completion:** 2023-11-20
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05518201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05518201, "Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05518201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*